White Paper

Reducing Risk During CAR T Cell Therapy Development And Manufacture

Scientist laboratory ipad iStock-1207515232

The predicted momentum of CAR T cell therapies has not fully materialized mainly arising from the inherent complexity of CAR T cell products, which results in a highly complex development process and, in turn, a slow speed-to-market. For example, there are many logistical challenges, including coordinating the variety of specialist scientists and the large number of reagents and consumable products required at different stages of production.

There are also numerous technical challenges related to accurately defining the product itself and establishing a robust and consistent process to manufacture the product at scale. To overcome these challenges, there are three main areas that should be prioritized during process development: equipment, reagents, and analytics. It is particularly important to consider these at the earliest stage possible, to help avoid late-stage protocol changes that can lead to costly delays.

In this paper we help you fully understanding the impact of optimizing these areas and how to identify the most appropriate options and strategies to achieve optimization.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online